Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $38.49, for a total value of $384,900.00. Following the completion of the sale, the senior vice president now directly owns 168,176 shares of the company's stock, valued at approximately $6,473,094.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Halozyme Therapeutics Trading Down 0.9 %
NASDAQ:HALO opened at $38.02 on Thursday. The company has a market capitalization of $4.83 billion, a PE ratio of 18.02, a price-to-earnings-growth ratio of 0.46 and a beta of 1.25. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. Halozyme Therapeutics, Inc. has a 52-week low of $29.85 and a 52-week high of $45.00. The stock has a fifty day simple moving average of $39.44 and a 200-day simple moving average of $37.76.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). The firm had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 3.33 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Elon’s New A.I. Device is About to Shock the World
From InvestorPlace | Ad
Using this device you see above…
Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in…
“The next step in human evolution.”
Click here to see the details because there’s a lot of money at stake.
A number of equities research analysts have commented on the company. TheStreet downgraded Halozyme Therapeutics from a "b-" rating to a "c+" rating in a report on Monday, January 22nd. Benchmark reissued a "buy" rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a report on Tuesday. HC Wainwright reissued a "buy" rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a report on Wednesday. Morgan Stanley reduced their target price on Halozyme Therapeutics from $61.00 to $59.00 and set an "overweight" rating for the company in a report on Tuesday, December 26th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, February 21st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $53.29.
Get Our Latest Research Report on HALO
Hedge Funds Weigh In On Halozyme Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the company. Rise Advisors LLC purchased a new stake in Halozyme Therapeutics in the 1st quarter worth approximately $25,000. Principal Securities Inc. acquired a new position in Halozyme Therapeutics in the 4th quarter valued at $34,000. Advisory Services Network LLC raised its holdings in Halozyme Therapeutics by 50.5% in the 1st quarter. Advisory Services Network LLC now owns 903 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 303 shares during the last quarter. Belpointe Asset Management LLC raised its holdings in Halozyme Therapeutics by 42.0% in the 1st quarter. Belpointe Asset Management LLC now owns 1,238 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 366 shares during the last quarter. Finally, Harbour Investments Inc. acquired a new position in Halozyme Therapeutics in the 4th quarter valued at $51,000. Hedge funds and other institutional investors own 97.79% of the company's stock.
About Halozyme Therapeutics
(
Get Free Report)
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
